Haleon plc (NYSE:HLN) Position Boosted by Greenleaf Trust

Greenleaf Trust boosted its holdings in Haleon plc (NYSE:HLN) by 8.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,225 shares of the company’s stock after acquiring an additional 1,333 shares during the quarter. Greenleaf Trust’s holdings in Haleon were worth $164,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of Haleon by 5.8% during the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock valued at $1,110,035,000 after purchasing an additional 5,768,117 shares during the period. Wellington Management Group LLP increased its stake in Haleon by 49.9% during the 3rd quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock valued at $96,833,000 after buying an additional 3,046,841 shares during the period. JPMorgan Chase & Co. raised its position in shares of Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after buying an additional 1,026,939 shares in the last quarter. Natixis Advisors LLC raised its position in shares of Haleon by 142.5% during the 3rd quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock worth $15,593,000 after buying an additional 866,070 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in shares of Haleon by 1,689.4% in the 3rd quarter. Jane Street Group LLC now owns 264,977 shares of the company’s stock worth $2,803,000 after acquiring an additional 250,169 shares during the period. Institutional investors own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.95.

Haleon Stock Performance

NYSE:HLN opened at $9.51 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average of $9.53 and a 200-day moving average of $9.77. Haleon plc has a twelve month low of $7.89 and a twelve month high of $10.80. The firm has a market cap of $43.03 billion, a price-to-earnings ratio of 27.96, a price-to-earnings-growth ratio of 2.69 and a beta of 0.28.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.